From 24 November to 5 December 2025, governments from around the world will gather in Samarkand, Uzbekistan for the 20th meeting of the Conference of the Parties (CoP20) to the Convention on International Trade in Endangered Species (CITES). This meeting comes at a moment of great consequence for some of the world’s most threatened species […]
The 78th World Health Assembly of the World Health Organization (WHO) has adopted the global traditional medicine strategy 2025-34 which sets out guiding principles, strategic objectives, directives and actions for WHO, its member states and other stakeholders to support the development of traditional, complementary and integrative medicine (TCIM). While TCIM plays an important role in […]
On 25 March, the National Medical Products Administration of China announced the release of the 2025 edition of the Chinese Pharmacopeia, to be implemented from 1 October this year. The release generated much fanfare because this latest edition removed 13 formulae which include pangolin in the ingredients. Sounds good! But don’t be fooled by the […]
Covering one packed agenda, four interventions and six hectic days, EIA campaigners share the highlights of the 78th meeting of the Standing Committee (SC78) of the Convention on International Trade in Endangered Species of Wild Fauna and Flora (CITES) in Geneva. Elephants Asian elephants SC78 marked EIA’s first engagement at CITES on the […]
The Government of China has made a commitment (Chinese) to supporting the development of substitutes for endangered wildlife used in traditional Chinese medicine (TCM). The announcement by the National Medical Products Administration of China (NMPA) is an encouraging step towards ending the use of threatened wildlife in TCM and represents tangible progress following a proposal […]
Norges Bank has divested from a major traditional Chinese medicine (TCM) company in the wake of EIA’s major exposé Investing in Extinction, which found the body parts of threatened leopards and pangolins being used as ingredients in at least 88 products. The bank cited an ‘unacceptable risk’ of Tianjin Pharmaceutical Da Re Tang Group Corp […]